Palisade Bio, Inc. (PALI)

Market Cap	4.25M
Revenue (ttm)	n/a
Net Income (ttm)	-13.50M
Shares Out	936.40K
EPS (ttm)	-23.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,180
Open	4.300
Previous Close	4.320
Day's Range	4.300 - 4.570
52-Week Range	3.820 - 36.600
Beta	1.29
Analysts	Strong Buy
Price Target	22.50 (+395.6%)
Earnings Date	Aug 9, 2024

About PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: PALI

Analyst Forecast

According to one analyst, the rating for PALI stock is "Strong Buy" and the 12-month stock price forecast is $22.5.

Price Target

$22.5

(395.60% upside)

Analyst Consensus: Strong Buy